Funding
Cancer
CANCER
The ProTarget trial is funded by the Danish Cancer Society (R270-A15507). Drugs and funding for data handling are supplied by Roche, Pfizer (for avelumab, as part of an alliance between Pfizer and Merck [CrossRef Funder ID: 10.13039/100009945]), GSK, and Incyte. ProTarget is an Investigator-Initiated Trial; none of the funders participated in study design or conduct, but eligible molecular alterations as defined in Table 